Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.

Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

by Zacks Equity Research

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News

by Zacks Equity Research

Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View

by Zacks Equity Research

TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.

How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.

Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down

by Zacks Equity Research

Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.

Core PCE Inflation at a 40-Year High in March

by Zacks Equity Research

Core PCE Inflation at a 40-Year High in March.

Mark Vickery headshot

PCE +6.6%, Another 40-Year High; XOM, CL, BMY Report

by Mark Vickery

Inflation was clear and present in March, but a large chunk of it was due to food and energy prices.

Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 2.08% and 3.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN

by Zacks Equity Research

Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.

Why Bristol-Myers (BMY) Might Surprise This Earnings Season

by Zacks Equity Research

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.

Alexandria (ARE) Q1 FFO Beats Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Alexandria Real Estate's (ARE) reports better-than-anticipated first-quarter 2022 performance attributable to healthy leasing activity and solid internal growth.

Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FLQL

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $77.56, marking a +0.36% move from the previous day.

Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

by Zacks Equity Research

Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $77.28 in the latest trading session, marking a +1.15% move from the prior day.

Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More

by Zacks Equity Research

Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.

Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FLQL

Exelixis (EXEL) Initiates Early Stage Study of Lymphoma

by Zacks Equity Research

Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures

by Zacks Equity Research

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH